BioCentury | Jul 25, 2005
Company News

Guilford, MGI deal

...injection is in Phase III trials for procedural sedation. GLFD also has two preclinical programs, NAALADase...
BioCentury | Jul 22, 2005
Top Story

MGI to acquire Guilford

...company's Aquavan propofol injection is in Phase III trials for procedural sedation. GLFD also has NAALADase...
BioCentury | Mar 30, 2004
Company News

Pfizer returns pain compounds to GLFD

...PFE returned to Guilford (GLFD) rights to develop and commercialize NAALADase inhibitors. Under a May 2003...
BioCentury | May 12, 2003
Company News

Guilford, Pfizer deal

...PFE received exclusive worldwide rights to a class of n-acetylated-alpha-linked-acidic-dipeptidase ( NAALADase ) inhibitors from GLFD...
...inhibitors, which are in preclinical testing. GLFD retains the right to continue to develop the NAALADase...
BioCentury | May 12, 2003
Finance

Ebb & Flow

...that it provided Pfizer (PFE) with exclusive worldwide rights to a class of n-acetylated-alpha-linked-acidic-dipeptidase ( NAALADase...
BioCentury | May 8, 2003
Company News

Guilford, Pfizer neurology deal

...PFE received exclusive worldwide rights to a class of n-acetylated-alpha-linked-acidic-dipeptidase ( NAALADase ) inhibitors from GLFD...
...inhibitors, which are in preclinical development. GLFD retains the right to continue to develop the NAALADase...
BioCentury | Dec 18, 2000
Clinical News

GPI-5693: Began Phase I trial

...Guilford Pharmaceuticals Inc. (GLFD), Baltimore, Md. Product: GPI-5693 Business: Neurological Therapeutic category: Neuroprotectant Target: NAALADase Description...
BioCentury | Nov 13, 2000
Clinical News

Guilford preclinical data

...GLFD said its inhibitors of NAALADase, which modulates the release of glutamate, reversed disease progression and...
...B10) Guilford Pharmaceuticals Inc. (GLFD), Baltimore, Md. Product:GPI-5693 inhibitor of N-acetylated alpha-linked acidic dipeptidase ( NAALADase...
BioCentury | Nov 1, 1999
Clinical News

Guilford preclinical data

...GLFD researchers reported that the company's NAALADase inhibitors induced the production of myelin, repaired damage and...
...the Society for Neuroscience meeting in Miami Beach. Guilford Pharmaceuticals Inc. (GLFD), Baltimore, Md. Product: NAALADase...
BioCentury | May 10, 1999
Clinical News

Guilford regulatory update

...disorders such as Parkinson's disease and Alzheimer's disease. Nos. 5,863,536 and 5,880,112 cover small molecule NAALADase...
Items per page:
1 - 10 of 13